TRIDENT LIFELINE
|
TRIDENT LIFELINE Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 10.22 | 5.52 | 5.23 | 4.93 |
| CEPS(Rs) | 13.90 | 6.01 | 5.55 | 5.19 |
| DPS(Rs) | - | - | - | - |
| Book NAV/Share(Rs) | 53.76 | 43.43 | 39.11 | 5.93 |
| Tax Rate(%) | 22.92 | 31.69 | 8.57 | -32.31 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 17.27 | 18.45 | 19.77 | 12.44 |
| EBIT Margin(%) | 20.41 | 20.94 | 22.29 | 14.28 |
| Pre Tax Margin(%) | 15.66 | 19.48 | 20.77 | 13.71 |
| PAT Margin (%) | 12.07 | 13.31 | 18.99 | 18.14 |
| Cash Profit Margin (%) | 18.38 | 15.48 | 20.14 | 19.07 |
| Performance Ratios | ||||
| ROA(%) | 8.64 | 7.92 | 16.00 | 30.72 |
| ROE(%) | 18.78 | 12.52 | 24.21 | 83.23 |
| ROCE(%) | 19.17 | 15.32 | 23.60 | 43.21 |
| Asset Turnover(x) | 0.72 | 0.60 | 0.84 | 1.69 |
| Sales/Fixed Asset(x) | 2.16 | 3.26 | 9.68 | 9.76 |
| Working Capital/Sales(x) | 2.36 | 1.41 | 0.84 | 7.03 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.46 | 0.31 | 0.10 | 0.10 |
| Receivable days | 86.30 | 104.41 | 98.21 | 83.27 |
| Inventory Days | 85.68 | 80.77 | 62.65 | 62.24 |
| Payable days | 110.89 | 90.79 | 111.70 | 177.25 |
| Valuation Parameters | ||||
| PER(x) | 25.16 | 29.71 | 30.41 | - |
| PCE(x) | 18.49 | 27.28 | 28.66 | - |
| Price/Book(x) | 4.78 | 3.77 | 4.07 | - |
| Yield(%) | - | - | - | - |
| EV/Net Sales(x) | 3.99 | 4.49 | 5.58 | 0.47 |
| EV/Core EBITDA(x) | 14.93 | 19.42 | 23.81 | 3.11 |
| EV/EBIT(x) | 19.55 | 21.43 | 25.04 | 3.31 |
| EV/CE(x) | 3.00 | 2.89 | 3.36 | 0.80 |
| M Cap / Sales | 3.40 | 4.22 | 5.77 | - |
| Growth Ratio | ||||
| Net Sales Growth(%) | 94.86 | 40.82 | 45.59 | - |
| Core EBITDA Growth(%) | 125.42 | 38.82 | 124.29 | - |
| EBIT Growth(%) | 90.02 | 32.26 | 127.18 | - |
| PAT Growth(%) | 76.69 | -1.31 | 52.46 | - |
| EPS Growth(%) | 85.19 | 5.46 | 6.01 | - |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.87 | 0.37 | 0.17 | 0.52 |
| Current Ratio(x) | 1.67 | 2.51 | 4.18 | 1.41 |
| Quick Ratio(x) | 1.16 | 1.91 | 3.57 | 0.92 |
| Interest Cover(x) | 4.29 | 14.42 | 14.67 | 24.72 |
| Total Debt/Mcap(x) | 0.18 | 0.10 | 0.04 | - |
Compare Financial Ratios of peers of TRIDENT LIFELINE
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| TRIDENT LIFELINE | ₹352.0 Cr | 7.9% | 15.3% | -9.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
TRIDENT LIFELINE Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| TRIDENT LIFELINE | 7.9% |
15.3% |
-9.1% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses
